LEXX earnings analysis
What we found in LEXX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lexaria reported a significant decline in revenue for Q2 2026, with total revenue decreasing to $20,000 from $531,923 a year earlier. Despite the revenue drop, the company achieved a narrower loss per share of -$0.06 compared to -$0.15 in the prior year. Operating expenses were reduced, reflecting operational efficiencies, but substantial doubt about the company's ability to continue as a going concern remains.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline Year-Over-Year
- Q2 revenue fell drastically by $511,923, down to $20,000 from $531,923 a year ago.
- Narrowed EPS Loss
- The diluted EPS loss improved to -$0.06 from -$0.15 year-over-year.
- Decreased Operating Expenses
- R&D expenses decreased by $4.24 million compared to last year, improving overall operating margins.
- Improved Cash Position
- Cash increased by $1.67 million in the nine months ended May 31, 2026, from the prior year.
- Equity Financing Boost
- Raised approximately $6.5 million in net proceeds from securities sales in 2026.
- Positive Results in R&D
- Positive findings reported from clinical studies using DehydraTECH technology.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue Collapse
- Total revenue decreased by 96.2% year-over-year, raising red flags about operational sustainability.
- Substantial Doubt About Going Concern
- Management has indicated there is substantial doubt regarding the company’s ability to continue operations for the next 12 months.
- Negative Operating Margin
- The operating margin remained significantly negative at -7259.5% in Q2 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.06
- Gross margin
- 100.0%
- Operating margin
- -7259.5%
What they said about what is next.
Management anticipates that cash resources will be sufficient to fund operations through the first quarter of fiscal year 2027, but existing cash will not meet long-term obligations.
The filing reads worse than the one before it.
What came before.
- 10-Q · April 13, 2026
- Lexaria reported Q2 revenue of $20,000 (down from $174,000 a year ago) and a narrower loss per share of $(0.06) versus $(0.15) a year ago. Management raised $6.52 million of equity proceeds in the six-month period,…
- 10-Q · January 13, 2026
- Lexaria reported zero revenue for the three months ended November 30, 2025 (vs. $183,923 in the prior-year quarter) while reducing its net loss to $1,595,007 and narrowing diluted loss per share to $(0.07) from $(0.16).…
- 10-Q · July 14, 2025
- Lexaria reported Q3 revenue of $174,000 (100% gross margin), up from $84,000 in the year‑ago quarter and flat sequentially. Losses widened: GAAP net loss was $(3,790,606) for the quarter (basic and diluted loss per…
- 10-Q · April 14, 2025
- Lexaria reported Q2 revenue of $174,000 (vs. $145,000 LYQ), beating the quarter estimate and delivering 100% gross margin, but losses widened as operating expenses jumped. EPS was a loss of $(0.15) (vs. $(0.06) LYQ) and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LEXX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever